In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sanofi outbids Novo with €45 per share offer for Ablynx, total of €3.8bn

Executive Summary

Public Belgian biotech Ablynx NV agreed to be acquired by Sanofi, which offered €45 per share ($59.92; a 37% premium) for a fully diluted equity value of €3.8bn ($5.1bn). The deal trumps an offer made earlier this month by Novo, which bid €28 per share plus CVRs for a total value of €2.3bn. Ablynx shareholders repeatedly rejected Novo’s advances, and Novo has stated that it will not make a revised offer.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash for Equity

Related Companies